Latest Insider Transactions at Recursion Pharmaceuticals, Inc. (RXRX)
This section provides a real-time view of insider transactions for Recursion Pharmaceuticals, Inc. (RXRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of RECURSION PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of RECURSION PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 02
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$91,576
$8.82 P/Share
|
|
Apr 01
2024
|
Terry Ann Burrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,467
+2.54%
|
-
|
|
Apr 01
2024
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,467
+1.62%
|
-
|
|
Apr 01
2024
|
R. Martin Chavez Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,001
+3.22%
|
-
|
|
Apr 01
2024
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,267
+2.1%
|
-
|
|
Mar 28
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-100.0%
|
$250,000
$10.1 P/Share
|
|
Mar 28
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,000
+50.0%
|
-
|
|
Mar 28
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
40,000
-3.69%
|
$400,000
$10.1 P/Share
|
|
Mar 28
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
25,000
-2.26%
|
-
|
|
Mar 21
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
8,000
-0.62%
|
$88,000
$11.02 P/Share
|
|
Mar 21
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.22%
|
$8,000
$1.06 P/Share
|
|
Mar 19
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
20,054
-0.28%
|
$200,540
$10.79 P/Share
|
|
Mar 13
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.03%
|
$275,000
$11.03 P/Share
|
|
Mar 13
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+2.96%
|
$75,000
$2.22 P/Share
|
|
Mar 12
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.05%
|
$250,000
$10.46 P/Share
|
|
Mar 12
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+2.99%
|
$75,000
$2.22 P/Share
|
|
Mar 06
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
25,000
-100.0%
|
$275,000
$11.56 P/Share
|
|
Mar 06
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
25,000
+50.0%
|
-
|
|
Mar 06
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
36,319
-3.17%
|
$399,509
$11.86 P/Share
|
|
Mar 06
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,924
+1.71%
|
$239,544
$6.94 P/Share
|
|
Mar 06
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
10,000
-0.9%
|
-
|
|
Mar 06
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
10,000
+0.89%
|
-
|
|
Mar 05
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
20,054
-0.28%
|
$240,648
$12.06 P/Share
|
|
Feb 22
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
8,000
-1.23%
|
$112,000
$14.89 P/Share
|
|
Feb 22
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.22%
|
$8,000
$1.06 P/Share
|
|
Feb 20
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
20,054
-0.14%
|
$240,648
$12.68 P/Share
|
|
Feb 15
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,148
-1.0%
|
$133,776
$12.43 P/Share
|
|
Feb 15
2024
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,379
-0.83%
|
$64,548
$12.43 P/Share
|
|
Feb 15
2024
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,172
-0.6%
|
$86,064
$12.43 P/Share
|
|
Feb 14
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-1.03%
|
$250,000
$10.71 P/Share
|
|
Feb 14
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+3.0%
|
$75,000
$2.22 P/Share
|
|
Feb 13
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.09%
|
$225,000
$9.86 P/Share
|
|
Feb 13
2024
|
Michael Secora Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+3.03%
|
$75,000
$2.22 P/Share
|
|
Feb 09
2024
|
Tina Marriott Larson President and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,800
-0.43%
|
$28,000
$10.09 P/Share
|
|
Feb 09
2024
|
Tina Marriott Larson President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
233,613
+13.95%
|
-
|
|
Feb 09
2024
|
Michael Secora Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,512
-0.22%
|
$25,120
$10.09 P/Share
|
|
Feb 09
2024
|
Michael Secora Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
182,849
+6.94%
|
-
|
|
Feb 09
2024
|
David J Mauro Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,892
-0.77%
|
$18,920
$10.09 P/Share
|
|
Feb 09
2024
|
David J Mauro Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,808
+9.89%
|
-
|
|
Feb 09
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,233
-0.29%
|
$32,330
$10.09 P/Share
|
|
Feb 09
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
344,597
+12.18%
|
-
|
|
Feb 07
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
48,272
-5.87%
|
$434,448
$9.22 P/Share
|
|
Feb 07
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+3.66%
|
$62,500
$2.48 P/Share
|
|
Feb 07
2024
|
Christopher Gibson Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
10,000
-1.25%
|
-
|
|
Feb 07
2024
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
10,000
+1.23%
|
-
|
|
Feb 06
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
11,447
-0.16%
|
$103,023
$9.3 P/Share
|
|
Jan 25
2024
|
Tina Marriott Larson President and COO |
SELL
Open market or private sale
|
Direct |
8,000
-1.89%
|
$80,000
$10.35 P/Share
|
|
Jan 25
2024
|
Tina Marriott Larson President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+1.86%
|
$8,000
$1.06 P/Share
|
|
Jan 23
2024
|
Blake Borgeson Director |
SELL
Open market or private sale
|
Direct |
20,054
-0.27%
|
$200,540
$10.58 P/Share
|
|
Jan 17
2024
|
Michael Secora Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,000
-2.49%
|
$250,000
$10.25 P/Share
|